- BioVaxys (BIOV) has completed a non-brokered private placement for gross proceeds of $405,000
- The company issued 4,050,000 units for $0.10 per unit
- The company also settled $150,000 in debt by issuing common shares
- BioVaxys Technology Corp is a clinical-stage biopharma company
- BioVaxys Technology Corp. (BIOV) opened trading at C$0.145
BioVaxys (BIOV) has completed a non-brokered private placement for gross proceeds of $405,000.
The company issued 4,050,000 units for $0.10 per unit. Each unit consists of one common share and one share purchase warrant. Each warrant is exercisable for one additional common share at an exercise price of $0.20 for 48 months.
All securities issued are subject to a statutory four-month hold period.
Proceeds will be used for working capital purposes.
The company also settled $150,000 in debt by issuing common shares at a deemed price of $0.20 per common share.
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumour types.
BioVaxys Technology Corp. (BIOV) opened trading at C$0.145.
